Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S and Coebergh JW: Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 44:1345–1389. 2008. View Article : Google Scholar

International Agency for Research on Cancer WHO Pancreas: Source: Globocan 2020. Available from: http://gcoiarcfr/today/data/factsheets/cancers/13-Pancreas-fact-sheetpdf. 2020

American Cancer Society: Cancer Facts and Figures. 2019.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI

Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V: Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar

Ilic M and Ilic I: Epidemiology of pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016. View Article : Google Scholar : PubMed/NCBI

Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and Parthenaki I: A systematic review of the burden of pancreatic cancer in europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI

Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, Cade JE, Burley VJ and Norat T: Body mass index, abdominal fatness and pancreatic cancer risk: A systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 23:843–852. 2012. View Article : Google Scholar

Nöthlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE and Kolonel LN: Body mass index and physical activity as risk factors for pancreatic cancer: The multiethnic cohort study. Cancer Causes Control. 18:165–175. 2007. View Article : Google Scholar : PubMed/NCBI

Pratapwar M, Stenzel AE, Joseph JM, Fountzilas C, Etter JL, Mongiovi JM, Cannioto R and Moysich KB: Physical inactivity and pancreatic cancer mortality. J Gastrointest Cancer. 51:1088–1093. 2020. View Article : Google Scholar

Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, et al: Cigarette smoking and pancreatic cancer: An analysis from the international pancreatic cancer case-control consortium (Panc4). Ann Oncol. 23:1880–1888. 2012. View Article : Google Scholar :

Iodice S, Gandini S, Maisonneuve P and Lowenfels AB: Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg. 393:535–545. 2008. View Article : Google Scholar : PubMed/NCBI

Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, et al: Pancreatitis and pancreatic cancer risk: A pooled analysis in the international pancreatic cancer case-control consortium (PanC4). Ann Oncol. 23:2964–2970. 2012. View Article : Google Scholar : PubMed/NCBI

Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Maire F, Hammel P, Ruszniewski P and Lévy P: Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: A national exhaustive series. Am J Gastroenterol. 103:111–119. 2008. View Article : Google Scholar : PubMed/NCBI

Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H and Li Z: Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 47:1928–1937. 2011. View Article : Google Scholar : PubMed/NCBI

McWilliams RR, Maisonneuve P, Bamlet WR, Petersen GM, Li D, Risch HA, Yu H, Fontham ET, Luckett B, Bosetti C, et al: Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: A pancreatic cancer case-control consortium (PanC4) analysis. Pancreas. 45:311–316. 2016. View Article : Google Scholar :

Pancreatic Cancer Europe Pancreatic Cancer Inequality Report. https://www.pancreaticcancereuropeeu/campaign/the-pancreatic-cancer-europe-inequality-report/. 2018

Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, et al: An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One. 8:e723112013. View Article : Google Scholar :

Whitcomb DC: Genetics of alcoholic and nonalcoholic pancreatitis. Curr Opin Gastroenterol. 28:501–506. 2012. View Article : Google Scholar : PubMed/NCBI

Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, et al: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 14:141–145. 1996. View Article : Google Scholar : PubMed/NCBI

Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O and Becker M: Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 25:213–216. 2000. View Article : Google Scholar

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI

Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M and Offerhaus JA: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 119:1447–1453. 2000. View Article : Google Scholar : PubMed/NCBI

Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, et al: The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 107:2005–2009. 2012. View Article : Google Scholar : PubMed/NCBI

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB and Syngal S: Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 302:1790–1795. 2009. View Article : Google Scholar : PubMed/NCBI

Moskaluk CA, Hruban H, Lietman A, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT and Kern SE: Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no 148 Online. Hum Mutat. 12:701998. View Article : Google Scholar

Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET and Bergman W: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 87:809–811. 2000. View Article : Google Scholar : PubMed/NCBI

Goldstein AM, Struewing JP, Fraser MC, Smith MW and Tucker MA: Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet. 41:421–424. 2004. View Article : Google Scholar : PubMed/NCBI

Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry D IV, Hartge P, Struewing JP, Hogg D, Halpern A, et al: Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: A melanoma case-control study. Cancer. 101:2809–2816. 2004. View Article : Google Scholar : PubMed/NCBI

Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI

Iacobuzio-Donahue CA: Genetic evolution of pancreatic cancer: Lessons learnt from the pancreatic cancer genome sequencing project. Gut. 61:1085–1094. 2012. View Article : Google Scholar

Noë M, Rezaee N, Asrani K, Skaro M, Groot VP, Wu PH, Olson MT, Hong SM, Kim SJ, Weiss MJ, et al: Immunolabeling of cleared human pancreata provides insights into three-dimensional pancreatic anatomy and pathology. Am J Pathol. 188:1530–1535. 2018. View Article : Google Scholar : PubMed/NCBI

Yamada M, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Sasaki K, Nagino M and Uesaka K: Microscopic venous invasion in pancreatic cancer. Ann Surg Oncol. 25:1043–1051. 2018. View Article : Google Scholar : PubMed/NCBI

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et al: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI

Fidler IJ and Poste G: The 'seed and soil' hypothesis revisited. Lancet Oncol. 9:8082008. View Article : Google Scholar

Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, et al: The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives. Signal Transduct Target Ther. 6:2492021. View Article : Google Scholar : PubMed/NCBI

Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar

Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, et al: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 52:231–240. 2020. View Article : Google Scholar

Hruban RH, Gaida MM, Thompson E, Hong SM, Noë M, Brosens LA, Jongepier M, Offerhaus GJA and Wood LD: Why is pancreatic cancer so deadly? The Pathologist's view. J Pathol. 248:131–141. 2019. View Article : Google Scholar : PubMed/NCBI

Cancer Genome Atlas Research Network: Electronic address: simpleandrew_aguirre@dfci.harvard.edu and Cancer Genome Atlas Research Network: Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 32:185–203.e13. 2017. View Article : Google Scholar

Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI

National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Pancreatic Adenocarcinoma. Version 1.2020. November 26–2019.

Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M and Conroy T: An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 11:17588359198755682019. View Article : Google Scholar :

Devisetty K and Wong SJ: Neoadjuvant versus induction chemotherapy: More than semantics. J Clin Oncol. 31:2971–2972. 2013. View Article : Google Scholar

NIH-National Cancer Institute NCI Dictionary of Cancer Terms. Available from: http://www.cancergov/dictionary. Accessed September 27, 2021.

National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Pancreatic Adenocarcinoma Version 2.0 2021-February 25 2021. www.nccn.org. 2021

Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, et al: Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or gemcitabine NabPaclitaxel: A single-center experience and a literature review. Cancers (Basel). 11:9812019. View Article : Google Scholar

Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, et al: Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/Nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 270:400–413. 2019. View Article : Google Scholar : PubMed/NCBI

Ghaneh P, Palmer DH, Cicconi S, Halloran C, Psarelli E, Rawcliffe C, Sripadam R, Mukherjee S, Wadsley J, Al-Mukhtar A, et al: ESPAC-5F: Four-arm, prospective, multi-center, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 38:4505. 2020. View Article : Google Scholar

Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, et al: Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for Borderline/locally advanced pancreatic cancer. Ann Surg. 273:341–349. 2021. View Article : Google Scholar

Kaufmann B, Hartmann D, D'Haese JG, Stupakov P, Radenkovic D, Gloor B and Friess H: Neoadjuvant treatment for borderline resectable pancreatic ductal adenocarcinoma. Dig Surg. 36:455–461. 2019. View Article : Google Scholar

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, et al: Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA. 315:1844–1853. 2016. View Article : Google Scholar

Hammel P, Lacy J, Portales F, Sobrero AF, Pazo Cid RA, Mozo JLM, Terrebonne E, Dowden SD, Li JS, Ong TJ, et al: Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 36:2042018. View Article : Google Scholar

Hurt CN, Falk S, Crosby T, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T and Mukherjee S: Long-term results and recurrence patterns from SCALOP: A phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer. 116:1264–1270. 2017. View Article : Google Scholar : PubMed/NCBI

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, et al: Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 14:317–326. 2013. View Article : Google Scholar : PubMed/NCBI

Pietrasz D, Turrini O, Vendrely V, Simon JM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, et al: How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort. Ann Surg Oncol. 26:109–117. 2019. View Article : Google Scholar

Katz MH, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, et al: Alliance for clinical trials in oncology (ALLIANCE) trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 17:5052017. View Article : Google Scholar :

Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D and Landry J: Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 123:3486–3493. 2017. View Article : Google Scholar : PubMed/NCBI

Sohal DP, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, et al: Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 36:2545–2556. 2018. View Article : Google Scholar : PubMed/NCBI

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI

Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: Results of secondary end points analyses. Br J Cancer. 99:6–13. 2008. View Article : Google Scholar : PubMed/NCBI

Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI

Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. Eur J Cancer. 49:593–603. 2013. View Article : Google Scholar

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar

Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, et al: Comparative effectiveness of gemcitabine plus nab-Paclitaxel and FOLFIRINOX in the First-Line setting of metastatic pancreatic cancer: A systematic review and Meta-Analysis. cancers (Basel). 11:4842019. View Article : Google Scholar

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI

Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L and Zhou J: Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: A randomized study. J Cancer Res Clin Oncol. 147:1529–1536. 2021. View Article : Google Scholar

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v56–v68. 2015. View Article : Google Scholar : PubMed/NCBI

Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, et al: Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 34:2784–2796. 2016. View Article : Google Scholar : PubMed/NCBI

Ghosn M, Saroufim A, Kattan J, Chahine G, Nasr F and Farhat F: Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Med Oncol. 29:2831–2837. 2012. View Article : Google Scholar : PubMed/NCBI

Dahan L, Phelip JM, Malicot KL, Williet N, Desrame J, Volet J, Petorin C, Malka D, Rebischung C, Aparicio T, et al: FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). 2018 ASCO Annual Meeting I Gastrointestinal (noncolorectal). J Clin Oncol. 36:40002018. View Article : Google Scholar

International Society of Geriatric Oncology Population Demographics-Cancer Epidemiology. 2021.

GBD 2017 Pancreatic Cancer Collaborators: The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 4:934–947. 2019. View Article : Google Scholar : PubMed/NCBI

Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, et al: Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 107:3362015. View Article : Google Scholar

Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L and Feliu J: Management of pancreatic cancer in the elderly. World J Gastroenterol. 22:764–775. 2016. View Article : Google Scholar :

Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza V, Iranzo V, et al: First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: A good choice beyond age. J Gastrointest Oncol. 10:910–917. 2019. View Article : Google Scholar :

Martin JL, Sidhu S, Benhayoun N, Dedonno M and Brenner WS: Dosing modifications to increase tolerability of gemcitabine and nab-paclitaxel in treatment of pancreatic cancer in the elderly. J Clin Oncol. 37:4412019. View Article : Google Scholar

Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP and O'Reilly EM: Treatment, outcomes, and clinical trial participation in elderly patients with metastatic pancreas adenocarcinoma. Clin Colorectal Cancer. 14:269–276.e1. 2015. View Article : Google Scholar

Guion-Dusserre JF, Bertaut A, Ghiringhelli F, Vincent J, Quipourt V, Marilier S, Tharin Z and Bengrine-Lefevre L: Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World J Gastroenterol. 22:9378–9386. 2016. View Article : Google Scholar : PubMed/NCBI

Yamamoto T, Sunakawa Y, Kubota Y, Tagawa T, Kaga Y, Uto TIY, Kitahara Y, Toshima H, Kobayashi K, Kitahara A, et al: Tolerability and clinical outcomes in elderly patients with advanced pancreatic cancer treated with FOLFIRINOX. J Clin Oncol. 34:4042016. View Article : Google Scholar

Alessandretti MB, Moreira RB, Brandao EP, Gomes JR and Amarante PM: Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma. J Clin Oncol. 33:4682015. View Article : Google Scholar

Michalaki V, Poydorou A, Vezakis A, Frangulidis G, Theodosopoulos T and Papadimitriou C: Gemcitabine plus capecitabine in elderly patients with advanced pancreatic cancer. Ann Oncol. 28:iii762017. View Article : Google Scholar

Marsanic P, Mellano A, Sottile A and De Simone M: Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. Med Biol Eng Comput. 55:1123–1127. 2017. View Article : Google Scholar : PubMed/NCBI

Sohal DP, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, et al: Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. Aug 5–2020.Epub ahead of print. View Article : Google Scholar

Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, et al: Phase I/II Trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol. 37:230–238. 2019. View Article : Google Scholar

Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI

Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, et al: Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM mutations in pancreatic cancer: Mutation prevalence and clinical outcomes from two canadian research registries. JCO Precision Oncology. Jan 19–2018. View Article : Google Scholar

Gudmundsdottir K and Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 25:5864–5874. 2006. View Article : Google Scholar : PubMed/NCBI

Rebelatto TF, Falavigna M, Pozzari M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S and Fazio N: Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev. 80:1018952019. View Article : Google Scholar : PubMed/NCBI

Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M and Khorana AA: Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 37:153–164. 2019. View Article : Google Scholar

National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Pancreatic Adenocarcinoma. Version 1.2021. October. 23–2020.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 381:317–327. 2019. View Article : Google Scholar : PubMed/NCBI

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al: Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 30:1959–1968. 2019. View Article : Google Scholar

Golan T, Hammel P, Reni M, et al: Final overall survival results from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. In: 2021 Gastrointestinal Cancer Symposium. Oral Presentation GI21 presented at ASCO-GI, 2021;

O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, et al: Randomized, multicenter, phase ii trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 38:1378–1388. 2020. View Article : Google Scholar : PubMed/NCBI

Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES and Reiss KA: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 122:333–339. 2020. View Article : Google Scholar :

Nishikawa G, Booth C and Prasad V: Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? Cancer. 126:4087–4088. 2020. View Article : Google Scholar : PubMed/NCBI

Rahma OE, Duffy A, Liewehr DJ, Steinberg SM and Greten TF: Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials. Ann Oncol. 24:1972–1979. 2013. View Article : Google Scholar : PubMed/NCBI

Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang HM, Oh D, Song TJ, Park DH, Lee SS, et al: Clinical outcomes of second-line chemotherapy after progression on Nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma. Cancer Res Treat. 52:254–262. 2020. View Article : Google Scholar :

Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH and Bekaii-Saab T: Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 123:4680–4686. 2017. View Article : Google Scholar : PubMed/NCBI

Cherri S, Noventa S and Zaniboni A: Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol. 27:1847–1863. 2021. View Article : Google Scholar :

Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, et al: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol. 32:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI

Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, et al: PANCREOX: A randomized phase III study of Fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 34:3914–3920. 2016. View Article : Google Scholar

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL and Wolff RA: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 113:2046–2052. 2008. View Article : Google Scholar : PubMed/NCBI

Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, et al: Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 112:1428–1434. 2015. View Article : Google Scholar :

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP and Bekaii-Saab TS: Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: A single-institute study. Oncology. 76:333–337. 2009. View Article : Google Scholar

Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A and Van Laethem JL: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer. 94:481–485. 2006. View Article : Google Scholar : PubMed/NCBI

Ramfidis VS, Syrigos KN and Saif MW: New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma. JOP. 14:344–346. 2013.PubMed/NCBI

Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J, Coriat R, et al: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort. Br J Cancer. 113:989–995. 2015. View Article : Google Scholar : PubMed/NCBI

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch Repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar

Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, et al: BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial. Nat Med. 26:878–885. 2020. View Article : Google Scholar : PubMed/NCBI

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L and Kurzrock R: Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-Targeted therapeutics. JCO Precis Oncol 2018. PO18.00183. 2018. View Article : Google Scholar

Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, et al: NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod Pathol. 33:38–46. 2020. View Article : Google Scholar :

O'Reilly EM and Hechtman JF: Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 30(Suppl 8): viii36–viii40. 2019. View Article : Google Scholar : PubMed/NCBI

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 21:271–282. 2020. View Article : Google Scholar

Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B and Chen LT: NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 108:78–87. 2019. View Article : Google Scholar

Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, et al: Hypermutation in pancreatic cancer. Gastroenterology. 152:68–74.e2. 2017. View Article : Google Scholar

Leem G and Song SY: Immunotherapy in pancreatic cancer; the road less traveled. Immunol Disord Immunother. 1:1062016. View Article : Google Scholar

Hayashi A, Hong J and Iacobuzio-Donahue CA: The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol. 18:469–481. 2021. View Article : Google Scholar : PubMed/NCBI

Nedaeinia R, Avan A, Manian M, Salehi R and Ghayour-Mobarhan M: EGFR as a potential target for the treatment of pancreatic cancer: Dilemma and controversies. Curr Drug Targets. 15:1293–1301. 2014. View Article : Google Scholar : PubMed/NCBI

Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI

Matsuoka T and Yashiro M: Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol. 22:776–789. 2016. View Article : Google Scholar :

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, et al: Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17:651–662. 2016. View Article : Google Scholar

Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ and Kalluri R: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546:498–503. 2017. View Article : Google Scholar : PubMed/NCBI

ClinicalTrials.gov: National Library of Medicine (US): 2000 Feb 29. Identifier NCT03608631, iExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation. August 1, 2018 [cited 2020 June 29]. Bethesda, MD, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03608631.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, et al: Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar :

Yachida S and Iacobuzio-Donahue CA: The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med. 133:413–422. 2009. View Article : Google Scholar : PubMed/NCBI

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, et al: Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 159:80–93. 2014. View Article : Google Scholar : PubMed/NCBI

van Duijnhoven FJB, Jenab M, Hveem K, Siersema PD, Fedirko V, Duell EJ, Kampman E, Halfweeg A, van Kranen HJ, van den Ouweland JM, et al: Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations. Int J Cancer. 142:1189–1201. 2018. View Article : Google Scholar :

Gorchs L, Ahmed S, Mayer C, Knauf A, Fernández Moro C, Svensson M, Heuchel R, Rangelova E, Bergman P and Kaipe H: The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 10:174442020. View Article : Google Scholar : PubMed/NCBI

Le Large TY, Bijlsma MF, Kazemier G, van Laarhoven HW, Giovannetti E and Jimenez CR: Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 44:153–169. 2017. View Article : Google Scholar : PubMed/NCBI

Sano M, Ijichi H, Takahashi R, Miyabayashi K, Fujiwara H, Yamada T, Kato H, Nakatsuka T, Tanaka Y, Tateishi K, et al: Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment. Oncogenesis. 8:82019. View Article : Google Scholar : PubMed/NCBI

Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC and Garrido-Laguna I: Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. J Clin Oncol. 36:5212018. View Article : Google Scholar

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, et al: Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7:400–409. 2017. View Article : Google Scholar : PubMed/NCBI

Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH and Hong SS: Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 5:9150–9168. 2014. View Article : Google Scholar : PubMed/NCBI

Herreros-Villanueva M and Bujanda L: Non-invasive biomarkers in pancreatic cancer diagnosis: What we need versus what we have. Ann Transl Med. 4:1342016. View Article : Google Scholar : PubMed/NCBI

Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, et al: The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 23:1713–1722. 2012. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Yang J, Li H, Wu Y, Zhang H and Chen W: Tumor markers CA19-9 CA242 and CEA in the diagnosis of pancreatic cancer: A meta-analysis. Int J Clin Exp Med. 8:11683–11691. 2015.

Kaur S, Baine MJ, Jain M, Sasson AR and Batra SK: Early diagnosis of pancreatic cancer: Challenges and new developments. Biomark Med. 6:597–612. 2012. View Article : Google Scholar : PubMed/NCBI

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR and Hayes DF: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 24:5313–5327. 2006. View Article : Google Scholar : PubMed/NCBI

Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007. View Article : Google Scholar

Ruivo CF, Adem B, Silva M and Melo SA: The biology of cancer exosomes: Insights and new perspectives. Cancer Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 523:177–182. 2015. View Article : Google Scholar : PubMed/NCBI

Hu W, Liu C, Bi ZY, Zhou Q, Zhang H, Li LL, Zhang J, Zhu W, Song YY and Zhang F: Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol Cancer. 19:1022020. View Article : Google Scholar : PubMed/NCBI